Halozyme Therapeutics, Inc. (HALO)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-11) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-17) · 99.1 | 8-K (2026-01-28) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-03) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-05) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-18) · 99.1 | 8-K (2025-01-08) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-31) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-20) · 99.1 | 8-K (2024-01-17) | ||
| 10-Q | Q3-2023 | 8-K (2023-11-06) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Income | ||
| Consolidated Statements of Comprehensive Income | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity | ||
| Notes | ||
| Business Combination | ||
| Certain Balance Sheet Items | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Earnings Per Share | ||
| Employee Savings Plan | — |
|
| Fair Value Measurement | ||
| Goodwill and Intangible Assets | ||
| Goodwill and Intangible Assets, Net | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Long-term Debt, Net | ||
| Organization and Business | ||
| Pay Vs Performance Disclosure | ||
| Revenue | ||
| Schedule Ii | — |
|
| Schedule Ii Valuation and Qualifying Accounts | — |
|
| Share-based Compensation | ||
| Stockholders' Equity | ||
| Summary of Significant Accounting Policies | ||